肥胖症药物治疗的不断发展的方法
Evolving Approaches for Pharmacological Therapy of Obesity.
作者信息
Chao Ariana M, Taylor Simeon, Moore Molly, Amaro Anastassia, Wadden Thomas A
机构信息
Johns Hopkins School of Nursing, Baltimore, Maryland, USA; email:
Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
出版信息
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):169-189. doi: 10.1146/annurev-pharmtox-031124-101146. Epub 2024 Dec 17.
Abstract
Obesity is a global health concern. Progress in understanding the physiology of obesity and weight reduction has provided new drug targets. Development and testing of new antiobesity medications (AOMs) has the potential to quickly expand options for treatment. In this review, we briefly summarize the physiology of obesity and weight reduction, as well as medications currently approved for weight management. We highlight the increasing use of incretin and nutrient-stimulated hormone-based therapies. We conclude with an overview of AOMs progressing through the pipeline and discuss their implications for the rapidly evolving field of obesity management.
摘要
肥胖是一个全球关注的健康问题。在理解肥胖生理学和体重减轻方面的进展提供了新的药物靶点。新型抗肥胖药物（AOMs）的研发和测试有可能迅速扩大治疗选择。在本综述中，我们简要总结了肥胖和体重减轻的生理学，以及目前批准用于体重管理的药物。我们强调了肠促胰岛素和营养刺激激素疗法的使用日益增加。我们最后概述了正在研发中的AOMs，并讨论了它们对迅速发展的肥胖管理领域的影响。
相似文献
1
Evolving Approaches for Pharmacological Therapy of Obesity.肥胖症药物治疗的不断发展的方法
Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):169-189. doi: 10.1146/annurev-pharmtox-031124-101146. Epub 2024 Dec 17.
2
Incretin-based therapies for obesity treatment.用于肥胖症治疗的基于肠促胰岛素的疗法。
Metabolism. 2015 Sep;64(9):967-81. doi: 10.1016/j.metabol.2015.05.012. Epub 2015 May 23.
3
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.肠促胰岛素激素激动剂：肥胖管理的当前及新兴药物治疗方法。
Pharmacotherapy. 2024 Sep;44(9):738-752. doi: 10.1002/phar.4607. Epub 2024 Sep 3.
4
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?胰高血糖素样肽-1受体激动剂：维持健康体重减轻的关键？
Cardiovasc Res. 2021 Aug 29;117(10):e120-e122. doi: 10.1093/cvr/cvab249.
5
Emerging pharmacotherapies for obesity: A systematic review.肥胖症的新兴药物疗法：一项系统评价。
Pharmacol Rev. 2025 Jan;77(1):100002. doi: 10.1124/pharmrev.123.001045. Epub 2024 Nov 22.
6
The incretin pathway as a new therapeutic target for obesity.肠促胰素途径作为肥胖的一个新的治疗靶点。
Maturitas. 2010 Nov;67(3):197-202. doi: 10.1016/j.maturitas.2010.06.018. Epub 2010 Jul 23.
7
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.在已经服用肠促胰岛素药物的 2 型糖尿病患者中，缓释纳曲酮/安非他酮安全有效：LIGHT 试验的事后分析。
Int J Obes (Lond). 2021 Aug;45(8):1687-1695. doi: 10.1038/s41366-021-00831-4. Epub 2021 Jun 3.
8
Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.基于肠促胰岛素的疗法与生活方式干预：注册营养师在肥胖症护理中不断演变的作用。
J Acad Nutr Diet. 2025 Mar;125(3):408-421. doi: 10.1016/j.jand.2024.10.023. Epub 2024 Nov 7.
9
Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.综述文章：肥胖的药物治疗管理——已批准药物、适应证和风险的最新信息。
Aliment Pharmacol Ther. 2024 Feb;59(4):475-491. doi: 10.1111/apt.17856. Epub 2024 Jan 2.
10
Treating the obese diabetic.治疗肥胖型糖尿病。
Expert Rev Clin Pharmacol. 2013 Mar;6(2):171-83. doi: 10.1586/ecp.13.5.
引用本文的文献
1
Probiotic Potentials and Protective Effects of LA-1 Against High-Fat Diet-Induced Obesity in Mice.LA-1对高脂饮食诱导的小鼠肥胖的益生菌潜力及保护作用
Nutrients. 2025 Jul 17;17(14):2346. doi: 10.3390/nu17142346.
2
Psychological Traits of Bariatric Surgery Candidates and Predictors of Outcomes.肥胖症手术候选人的心理特征及手术结果的预测因素
J Pers Med. 2025 May 26;15(6):215. doi: 10.3390/jpm15060215.
本文引用的文献
1
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.全球范围内 1990 年至 2022 年体重不足和肥胖趋势：对 3663 项具有 2.22 亿儿童、青少年和成年人代表性的人群研究进行的汇总分析。
Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29.
2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.胰高血糖素和 GLP-1 受体双重激动剂索马鲁肽治疗肥胖症的随机、双盲、安慰剂对照、剂量探索 2 期临床试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
3
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.一种与 GLP-1 类似物偶联的 GIPR 拮抗剂在临床前和 1 期研究中可促进体重减轻，并改善代谢参数。
Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5.
4
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.一项在中国超重成年人或肥胖成年人中进行的 mazdutide 的 2 期随机对照试验。
Nat Commun. 2023 Dec 14;14(1):8289. doi: 10.1038/s41467-023-44067-4.
5
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.在肥胖成年人中继续使用替尔泊肽治疗以维持体重减轻：SURMOUNT-4 随机临床试验。
JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945.
6
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.生活方式改变与第二代抗肥胖药物的作用：比较、问题与临床机遇。
Curr Obes Rep. 2023 Dec;12(4):453-473. doi: 10.1007/s13679-023-00534-z. Epub 2023 Dec 2.
7
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
8
Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study.代谢综合征特征患者中 CB1R 反向激动剂 INV-202 的作用。一项随机、安慰剂对照、双盲 1b 期研究。
Diabetes Obes Metab. 2024 Feb;26(2):642-649. doi: 10.1111/dom.15353. Epub 2023 Nov 8.
9
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.超重或肥胖成年人强化生活方式干预后使用替尔泊肽：SURMOUNT-3 期临床试验。
Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15.
10
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.每日一次 HU6 与安慰剂在非酒精性脂肪性肝病和高 BMI 人群中的安全性和疗效：一项随机、双盲、安慰剂对照的 2a 期临床试验。
Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1094-1105. doi: 10.1016/S2468-1253(23)00198-X. Epub 2023 Oct 5.
Zotero 插件